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Background and aim of the study: To compare four risk scores with regard to their validity to predict in-
hospital mortality after heart valve surgery in a multicenter patient population of China.
Materials and methods: From January 2009 to December 2012, data from 12,412 consecutive patients
older than 16 years who underwent heart valve surgery at four cardiac surgical centers were collected
and scored according to the EuroSCORE II, Ambler risk score, NYC risk score, and STS risk score. The
patients were divided into two subgroups according to the types of valve procedures, and the perfor-
mance of the four risk scores for each group was assessed. Calibration was assessed by the Hosmer
eLemeshow (H-L) test. Discrimination was tested by calculating the area under the receiver operating
characteristic (ROC) curve.
Results: Observed mortality was 2.09% overall. The EuroSCORE II, Ambler score, and NYC score over-
predicted observed mortality (HosmereLemeshow: P ¼ 0.002, P < 0.0001, and P < 0.0001, respectively)
and the STS score underpredicted observed mortality (HosmereLemeshow: P ¼ 0.001). The discrimi-
native power in the entire cohort for in-hospital mortality was highest for the STS score (0.735), followed
by the EuroSCORE II score (0.704), NYC score (0.693), and Ambler score (0.674). Meanwhile, the STS score
and EuroSCORE II give an accurate prediction in patients undergoing single valve surgery compared with
the Ambler score and NYC score. However, all four risk scores give an imprecise prediction in patients
undergoing multiple valve surgery.
Conclusions: Both the STS score and Euroscore II, especially the STS score, were suitable for individual
operative risk in Chinese patients undergoing single valve surgery compared with the Ambler score and
NYC score, however, all four risk scores were not suitable for prediction in Chinese patients undergoing
multiple valve surgery. Therefore, the creation of a new model which accurately predicts outcomes in
patients undergoing multiple valve surgery is possibly required in China.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Valvular heart disease (VHD) is the most frequent acquired
cardiac disease in China, and it also remains frequent in developed
countries, where its prevalence increases sharply with age, because
of the predominance of degenerative valvular diseases.1 Preopera-
tive risk prediction models play a vital role in current valvular
surgical practice. Such models can serve as hospital performance
benchmarks, and can also be used to provide the surgeon and theracic surgery, Changhai Hos-
epublic of China. Tel.: þ86 21
x. Zhang), hanlindoctor@
r Inc. This is an open access article upatient with a quantitative estimate of the procedural risk, or to
study the impact of particular risk factors on outcome.2
Over the recent decades, a number of excellent risk score
systems have been developed to predict mortality for heart valve
surgery, such as Veterans Administration (VA) score, the Euro-
pean System for Cardiac Operative Risk Evaluation (EuroSCORE),
Northern New England Cardiovascular Disease Study Group
(NNE) score, Society of Cardiothoracic Surgeons of Great Britain
and Ireland (Ambler) score, New York’s cardiac surgery reporting
system (NYC) score, and Society of Thoracic Surgeons (STS)
score.3e11 These scores have been derived from analysis of clin-
ical variables and outcomes in large cardiovascular surgery da-
tabases and have subsequently been validated in prospectivender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Synopsis of original data of four risk scores.
Risk score Region Model design Study period Year of publication Number of patients (centers) H-L test ROC area
EuroSCORE II5 Europe Cardiac surgery 2010 2011 22,381 (154) NA 0.81
Ambler score6 UK A/M combined A þ M 1995e2003 2004 32,893 (30) 0.78 0.77
NYC score9 USA Valve/valve with CABG 2007e2009 2013 21,828 (33) 0.52 0.79
STS score10,11 USA Valve/valve with CABG 2002e2006 2008 21,1420 (NA) NA 0.80/0.75
A, aortic valve; CABG, coronary artery bypass graft; H-L, HosmereLemeshow; M, mitral valve; NYC, New York’s cardiac surgery reporting system; ROC, receiver operator
characteristics; STS, Society of Thoracic Surgeons database.
Table 2
Risk score items.
Risk factors EuroSCORE II Ambler NYC STS
Age O O O O
Female O O O O
BMI O
BSA O
Hypertension O O
Diabetes O O O
Chronic pulmonary disease O O
Peripheral vascular disease O O O
CVD O O
CVA O
N/M mob O
Serum creatinine O O O
Creatinine clearance O
Dialysis O O O O
Left main disease O
Active endocarditis O O O
Prior cardiac operation O O O O
Immunosuppressive treatment O
Atrial ﬁbrillation O O
Heart block O
Ventricular tachycardia/ﬁbrillation O O
Recent MI O O O
Unstable angina O
CCS O
NYHA O O
Congestive heart failure O
Hemodynamic state unstable O
Hemodynamic state shock O O
IABP or inotropes O O
Ejection fraction O O O O
Coronary artery disease O
Left main disease O
PA systolic pressure O
Surgical priority O O O
Weight of procedure O
Mitral valve replacement O O
Mitral valve repair O
Aortic and mitral valve surgery O
Multiple valve repair or replacement O
Concomitant tricuspid surgery O
Concomitent CABG surgery O O
Concomitant thoracic aorta surgery O
Mitral valve stenosis O
Tricuspid valve insufﬁciency O
BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass
grafting; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular accident or
stroke; CVD, cerebrovascular disease; IABP, intra-aortic balloon pump; MI,
myocardial infarction; N/M mob, neurological or musculoskeletal dysfunction
severely affecting mobility; NYC, New York’s cardiac surgery reporting system;
NYHA, New York Heart Association; PA, pulmonary artery; STS, Society of Thoracic
Surgeons database.
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outcome prediction at different surgical centers, both at the
overall institutional level and the patient level, and if possible
they could be used in different countries.
Changes in cardiac surgery case mix, surgical techniques and
clinical outcomes continuously lead investigators to improve and
modify currently available risk-stratiﬁcation systems. All improve-
ments and modiﬁcations require further validation tests for
different patient populations globally. Despite the existence of a
few comparative studies of different risk scores,12e20 an objective
evaluation of the performance of the above scores in predicting in-
hospital mortality after heart valve surgery in a multicenter patient
population of China has not been performed. Hence, the aim of this
studywas to compare four risk scores whichwere published during
the last 10 years with regard to their validity to predict in-hospital
mortality after heart valve surgery in a multicenter study con-
ducted in China.
Patients and methods
Study population
In this multicenter retrospective study, all patients older than 16
years who underwent heart valve surgery at four cardiac surgical
centers in the period from January 2009 to December 2012. The
cardiac surgical units participating in this study included Fu Wai
Hospital in Beijing, Changhai Hospital of Shanghai, Zhongshan
Hospital of Fudan University in Shanghai, and Guangdong Cardio-
vascular Institute in Guangzhou. Patients who underwent single
valve surgery or multiple valve surgery with concomitant CABG or
atrial ﬁbrillation procedures were included in this study. However,
patients who had only pulmonary valve surgery were excluded
because of their relatively small numbers.
Data collection
Information on patients and the procedural risk factors for all
patients was collected from the local computerized database which
was designed by the Department of Cardiothoracic Surgery, Chan-
ghai Hospital, Shanghai, China. Thismulticenter retrospective study
was supported by Public Specialty Fund of Health Ministry
(200802096). The steering committee which includes cardiac sur-
geons and researchers from Changhai Hospital of Shanghai was in
charge of supervision and coordination of institution recruitment
and data collection. All 4 participating institutions received detailed
information at the beginning of the project on data collection re-
quirements and deﬁnitions of variables. Data were collected from
January 2008 to December 2013. Two reviewers from the data
processing center audited at a 6-month interval. The data submit-
ted by the hospitals were compared with information in the
medical records. When disagreement occurred, a physician adju-
dicated the disagreement to determine the ﬁnal value. The review
of these records was approved by our institutional committee for
human research.Risk factors in the different risk models were selected strictly
from our local database in which data included patient
demographics, comorbidity, valve disease severity, procedural
details, and outcomes. We also excluded patients who had missing
information on key predictors: age, gender, operation sequence,
and number and position of implanted heart valves. Operative risk
was estimated by the EuroSCORE II,5 the Ambler risk score,6 the
Table 3
Distribution of valve procedures.
Procedure Number Concomitant CABG (%) Unadjusted mortality
Single valve 5152 298 (5.78%) 1.63%
A 2283 138 (6.04%) 2.15%
M 2221 156 (7.02%) 1.08%
T 648 4 (0.62%) 1.70%
Multiple valve 7260 176 (2.42%) 2.42%
A, M 1425 36 (2.53%) 2.11%
A, T 103 3 (2.91%) 5.83%
A, P 15 0 (0.00%) 0.00%
M, T 3495 91 (2.60%) 2.40%
T, P 9 1 (11.11%) 11.11%
A, M, T 2206 44 (1.99%) 2.45%
A, M, P 1 0 (0.00%) 0.00%
A, T, P 1 0 (0.00%) 0.00%
M, T, P 2 0 (0.00%) 0.00%
A, M, T, P 3 1 (33.33%) 33.33%
Total 12,412 474 (3.82%) 2.09%
CABG, coronary artery bypass; A, aortic valve; M, mitral valve; T, tricuspid valve; P,
pulmonic valve.
Table 4
Model calibration of four risk scores in entire cohort.
Observed
mortality (%)
Predicted
mortality (%)
H-L test
(P value)
O/E ratio
EuroSCORE II 2.09 2.42 0.002 0.86
Ambler score 2.09 3.07 <0.0001 0.68
NYC score 2.09 2.57 <0.0001 0.81
STS score 2.09 1.33 0.001 1.57
H-L, hosmerelemeshow; NYC, New York’s cardiac surgery reporting system; O/E,
observed/expected; STS, Society of Thoracic Surgeons database.
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according to the published deﬁnitions (Table 1). Table 2 summa-
rizes the score items, which were evaluated by the four risk score
systems. The patients were then allocated to two subgroups ac-
cording to the valve procedures: single valve surgery group and
multiple valve surgery group. The predicted mortality was
compared to observed mortality for the entire cohort population
and for each subgroup.
Outcome endpoint
The outcome endpoint of this study was in-hospital mortality,
death in our hospital, as the operation took place before discharge
from hospital.
Statistical analysis
Statistical analyses were performed with SPSS version 19.0
(SPSS Inc., Chicago, Illinois). Continuous variables were expressed
as mean  standard deviation, and categorical variables were
expressed as percentages. A P value of less than 0.05 was consid-
ered signiﬁcant. Missing data are uncommon in our study, with a
frequency of less than 1% missing for most variables. Model vari-
ables with more than 1% missing were ‘body surface area (BSA)’
(3.88%), ‘body mass index (BMI)’ (3.88%), ‘Serum creatinine’ (3.11%),
and ‘left ventricular ejection fraction (EF)’ (4.40%). To make full use
of the available data, missing values were replaced by the single
imputation technique21 before the risk score was calculated. For
example, binary risk factors were modeled as yes versus no or
missing. Thus, missing values were analyzed as if the endpoint did
not occur. Missing data on categorical variables were imputed to
the lowest risk value. Missing data on continuous variables were
imputed to the conditional median.
Performance of the four risk score systems was assessed by
comparing the observed and expected in-hospital mortality. Model
calibration (statistical precision) was analyzed by HosmereLeme-
show goodness-of-ﬁt statistic.22 A well-calibrated model gives a P
value greater than 0.05. Model discrimination (statistical accuracy)
was tested by calculating C-index, evaluated by calculating the
areas under ROC curves, which was used to assess how well the
model could discriminate between survivors and non-survivors.23
The value of the C-index ranges from 0.5 (no ability to discrimi-
nate) to 1.0 (full ability to discriminate). The discriminative power
of the model is considered reasonable when the C-index is more
than 0.7 and strong when the C-index exceeds 0.8.
Results
Patient population and demographics
All 12,429 patients who underwent valve surgery procedures
between January 2009 and December 2012 were evaluated for
study inclusion; 17 patients were excluded for only pulmonary
valve surgery. Finally, a database including 12,412 patients was
obtained. The distribution of valve surgeries performed is shown in
Table 3.
Overall, the average age 49.412.9 years, 53.2% of patients were
female, and mean left ventricular ejection fraction (EF) was
61.1% 8.7%. Of the 12,412 patients, 15.1% of patients were smokers,
16.0% had hypertension, 4.4% had diabetes mellitus, 5.3%
had chronic lung disease, 1.3% had peripheral vascular disease, 3.7%
had cerebrovascular accident or stroke, 0.6% had renal failure, 3.6%
had active endocarditis, 42.7% had atrial ﬁbrillation, 49.8% had
pulmonary hypertension, 5.2% had previous valve surgery, 56.0%
had New York Heart Association (NYHA) IIIeIV, 0.4% had Left maindisease, 0.2% had recent myocardial infarction, and 0.5% had
emergency valve surgery.
Calibration and discriminatory power for four risk scores
Overall mortality
There were 260 deaths observed, giving an overall observed
mortality rate of 2.09%. Predicted mortality rate for the EuroSCORE
II, Ambler score, NYC score, and STS score were 2.42%, 3.07%, 2.57%,
and 1.33%, respectively. Table 4 and Fig. 1 show the model perfor-
mance of the four risk scores in entire cohort. The results mean that
the EuroSCORE II, Ambler score, and NYC score overpredicted
observed mortality (HosmereLemeshow: P ¼ 0.002, P < 0.0001,
and P < 0.0001, respectively) and the STS score underpredicted
observed mortality (HosmereLemeshow: P ¼ 0.001).
The discriminative power (i.e. the area under the ROC curve) for
in-hospital mortality was highest for the STS score (0.735), fol-
lowed by the EuroSCORE II score (0.704), NYC score (0.693), and
Ambler score (0.674) (Fig. 2). It means that both the EuroSCORE II
model and the STS score showed good discrimination in predicting
in-hospital mortality in entire cohort.
Mortality in two subgroups
There were 5152 and 7260 patients classiﬁed as single valve
surgery group and multiple valve surgery group, respectively. In-
hospital mortality was 1.63% in single valve surgery group (84
deaths in 5212patients) and 2.42% in multiple valve surgery group
(176/7260 patients).
Predictedmortality rate for the EuroSCORE II, Ambler score, NYC
score, and STS score in single valve surgery groupwere 1.51%, 2.00%,
1.14%, and 1.79%, respectively. The observed/expected (O/E) ratio of
in-hospital mortality 1.08, 0.82, 1.43, and 0.91, respectively. The
details of the four risk scores performance for single valve surgery
group are shown in Table 5. The results mean that the STS score and
Fig. 1. (AeD) Calibration plots of the European System for Cardiac Operative Risk Evaluation (EuroSCORE) II, Society of Cardiothoracic Surgeons of Great Britain and Ireland (Ambler)
score, New York’s cardiac surgery reporting system (NYC) score, and Society of Thoracic Surgeons (STS) score in entire cohort. (A). Calibration plots of the STS score in entire cohort.
(B). Calibration plots of the EuroSCORE II in entire cohort. (C). Calibration plots of the Ambler score in entire cohort. (D). Calibration plots of the NYC score in entire cohort.
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risk in patients undergoing single valve surgery compared with the
Ambler score and NYC score.Fig. 2. Receiver operating characteristic (ROC) curves for the European System for
Cardiac Operative Risk Evaluation (EuroSCORE) II (purple line), Society of Cardiotho-
racic Surgeons of Great Britain and Ireland (Ambler) score (green line), New York’s
cardiac surgery reporting system (NYC) score (yellow line), and Society of Thoracic
Surgeons (STS) score (blue line). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)Predictedmortality rate for the EuroSCORE II, Ambler score, NYC
score, and STS score in multiple valve surgery group were 3.12%,
4.32%, 3.27%, and 1.11%, respectively. The observed/expected (O/E)
ratio of in-hospital mortality 0.78, 0.56, 0.74, and 2.18, respectively.
The details of the four risk scores performance for multiple valve
surgery group are shown in Table 6. The results mean that all four
risk scores give an imprecise prediction for individual operative risk
in patients undergoing multiple valve surgery.Discussion
Valvular heart disease (VHD) is an important and challenging,
clinical entity in China. In the past, valvular heart diseases were
typically caused by rheumatic heart disease, which remains a major
public-health problem. However, during the recent years, rheu-
matic disease has fallen substantially,24 and the prevalence of
degenerative valvular diseases are increasing sharply with aging of
the population. Despite improvements of surgical techniques andTable 5
Predictive ability of four risk scores in single valve surgery.
Observed
mortality (%)
Predicted
mortality (%)
H-L test
(P value)
ROC area
(C-index)
EuroSCORE II 1.63 1.51 0.556 0.713
Ambler score 1.63 2.00 0.001 0.700
NYC score 1.63 1.14 <0.0001 0.683
STS score 1.63 1.79 0.317 0.747
H-L, HosmereLemeshow; NYC, New York’s cardiac surgery reporting system; ROC,
receiver operator characteristics; STS, Society of Thoracic Surgeons database.
Table 6
Predictive ability of four risk scores in multiple valve surgery.
Observed
mortality (%)
Predicted
mortality (%)
H-L test
(P value)
ROC area
(C-index)
EuroSCORE II 2.42 3.12 0.006 0.726
Ambler score 2.42 4.32 0.001 0.671
NYC score 2.42 3.27 0.002 0.681
STS score 2.42 1.11 <0.0001 0.691
H-L, HosmereLemeshow; NYC, New York’s cardiac surgery reporting system; ROC,
receiver operator characteristics; STS, Society of Thoracic Surgeons database.
C. Wang et al. / Heart & Lung 45 (2016) 423e428 427perioperative care, open heart valve operations still carry a risk of
mortality and morbidity.
Risk prediction scores play an important role in current valvular
surgical practice. Appropriate risk assessment is vital in obtaining
the patients informed consent, and in monitoring the quality of
operations performed by surgeons, and of the institutions. Various
score systems have been developed to predict mortality for heart
valve surgery in large multicenter valvular surgery databases, such
as the EuroSCORE II, Ambler score, NYC score, and STS score.5,6,8e11
Of these risk prediction models, the EuroSCORE II and STS score
were highly successful and used worldwide in the daily clinical
activities. These scores have been derived from analysis of clinical
variables and outcomes in large cardiovascular surgery databases
and have subsequently been validated in prospective studies. It is
desirable that these models should be useful for outcome predic-
tion at different surgical centers, both at the overall institutional
level as well as the patient level, and if possible in different coun-
tries. However, the relative systemic validation of above risk scores
in a multicenter patient population currently remains unclear in
China. Therefore, we have analyzed the predictive value of these
risk scores for predicting operative mortality in patients undergo-
ing heart valve surgery.
Our study population was selected from 4 representative in-
stitutions located in the developed area of China, and the popula-
tionwas drawn from approximately half of the area of China. In our
study, both the STS score and Euroscore II, especially the STS score,
were suitable for individual operative risk prediction in patients
undergoing single valve surgery compared with the Ambler score
and NYC score, however, all four risk scores were not suitable for
prediction in patients undergoing multiple valve surgery. This
result was similar with our recent clinical researches which were
designed in multicenter study.25,26 The reasons are likely to be
multi-factorial. First, the Chinese lifestyle is now more similar to
lifestyles in Europe and the United States, especially the daily diet;
however, a number of differences still remain. In regard to genetics,
the heterogeneity in racial backgrounds, education, workload, ac-
cess to medical facilities, and social systems, the baseline of the
prevalence of risk factors in our population differed from those of
the Europe and the United States. The population included in our
study was younger, included a greater proportion of females, had
less chronic lung disease, peripheral vascular disease, renal
dysfunction, coronary artery disease, recent myocardial infarction,
emergency surgery, and had higher active endocarditis, atrial
ﬁbrillation, and pulmonary hypertension at the time of valve sur-
gery.25,26 Second, the epidemiology of heart valve disease in China
is different from that of western industrialized countries. Due to
these different epidemiologies, there will most likely be some dif-
ferences in the operative procedure, and in the intensive care
therapy and post-surgical treatment that may, at least in theory,
lead to different individual patient predictions for mortality.
Rheumatic heart disease, which does not inﬂuence a particular
valve, remains the key cause of heart valve disease at our in-
stitutions. Hence, multiple valve procedures are common, as shownin Table 2, and account for approximately 58.5% of all valve pro-
cedures in our study population. Multiple valve procedures were
not included in the STS score because that accounted for a small
number of procedures in the STS database, and the risk prediction
algorithm of single valve surgery may lead to a decrease in pre-
dictive power if applied in multiple valve surgery. Third, the
candidate predictor variables were selected relative completely by
the STS score compared with other risk scores. Some valve disease-
speciﬁc risk factors are included in the STS score development, such
as characteristic of valve pathological changes, which is related
with the operative treatment of valvular heart disease.27 Mean-
while, the statistical analysis method inclusion of predictor vari-
ables in model development of STS score was different from other
risk scores. Interaction terms with two candidate variables were
ﬁrstly used in the STS score development.10,11 Therefore, it is not a
surprise that the STS score gives the best calibration and discrim-
inative power in single valve surgery. Moreover, differences be-
tween the available risk algorithms regarding score design and the
patient population on which the score development was based
could inﬂuence their accuracy and performance. The major reasons
include differences in risk factors selected, weighting of the risk
factors, patient characteristics, and operative techniques.
Limitations of the study
There are several limitations in our study. First, the endpoint
was deﬁned as hospital death recorded in the original medical re-
cord; however, the true mortality after valve surgery would be
higher. The EuroSCORE II deﬁned the endpoint as death either prior
to discharge from the hospital or within 30 or 90 days of the sur-
gery. In contrast to 30 days or even 60 or 90 days mortality, in-
hospital mortality is a well-ﬁxed and clear-cut binary outcome
parameter, which can easily be crosschecked with the data pool
provided by the hospital administration system. Second, as a
retrospective investigation, the incorrect and missing data in the
original medical records could not be recollected and the deﬁnition
of risk factors is not same in different risk score systemwhich could
affect the result of the risk algorithm. These above mentioned
limitations may lead to some bias in our study results.
In conclusion, we conclude that both the STS score and Euro-
score II, especially the STS score, were suitable for individual
operative risk in Chinese patients undergoing single valve surgery
compared with the Ambler score and NYC score, however, all four
risk scores were not suitable for prediction in Chinese patients
undergoing multiple valve surgery. Our research is a multicenter
study in a Chinese population and our ﬁndings include that the
creation of a new model which accurately predicts outcomes in
patients undergoing multiple valve surgery is possibly required in
China.
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